Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse large B-cell lymphoma arising from the central nervous system.
Biomarker and diagnostic research for diffuse large B-cell lymphoma of the central nervous system has been reported in the published literature.
3 clinical trials registered. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.
25 publications have been identified in PubMed for diffuse large B-cell lymphoma of the central nervous system. Research spans Case Report / Case Series (36%), Diagnostic / Biomarker (20%), and Basic Science / Preclinical (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 9 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:33 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
36%
Testing and diagnosis research | 5 | 20% |
Laboratory research | 5 | 20% |
Research summaries | 3 | 12% |
Clinical study results | 2 | 8% |
Disease patterns and progression | 1 | 4% |
Moassefi M (2026). [PMID: 42081255](https://pubmed.ncbi.nlm.nih.gov/42081255/). *Cancer Res Commun*. [Diagnostic / Biomarker]
Shi Y (2026). [PMID: 41580449](https://pubmed.ncbi.nlm.nih.gov/41580449/). *Sci Rep*. [Diagnostic / Biomarker]
Wang H (2026). [PMID: 41999193](https://pubmed.ncbi.nlm.nih.gov/41999193/). *Int J Cancer*. [Clinical Trial Publication]
Rodríguez Morales JA (2026). [PMID: 41710844](https://pubmed.ncbi.nlm.nih.gov/41710844/). *Cureus*. [Case Report / Case Series]
Li C (2026). [PMID: 41352379](https://pubmed.ncbi.nlm.nih.gov/41352379/). *Free Radic Biol Med*. [Basic Science / Preclinical]
Liang T (2026). [PMID: 42208778](https://pubmed.ncbi.nlm.nih.gov/42208778/). *Genomics*. [Basic Science / Preclinical]
Zhang Y (2025). [PMID: 40918104](https://pubmed.ncbi.nlm.nih.gov/40918104/). *Front Immunol*. [Case Report / Case Series]
Shooshani T (2025). [PMID: 40150122](https://pubmed.ncbi.nlm.nih.gov/40150122/). *Diagnostics (Basel)*. [Case Report / Case Series]
Zeng Y (2025). [PMID: 41023895](https://pubmed.ncbi.nlm.nih.gov/41023895/). *BMC Med Imaging*. [Diagnostic / Biomarker]
Tian C (2025). [PMID: 39150595](https://pubmed.ncbi.nlm.nih.gov/39150595/). *J Imaging Inform Med*. [Basic Science / Preclinical]
AI-curated news mentioning diffuse large B-cell lymphoma of the central nervous system
Updated Aug 4, 2026
A study highlights the presence of SETD2 mutations in primary central nervous system T cell lymphoma, which affects multiple brain and spinal cord lesions. This discovery may provide insights into the genetic underpinnings of this rare lymphoma subtype.